NASDAQ:INSMInsmed Stock Price, Forecast & News

Insmed's stock was trading at $21.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, INSM stock has increased by 17.4% and is now trading at $24.95. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Insmed.

Insmed is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Insmed.

Insmed Incorporated (NASDAQ:INSM) posted its quarterly earnings results on Thursday, April, 30th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.72) by $0.02. The biopharmaceutical company earned $36.90 million during the quarter, compared to analysts' expectations of $34.81 million. Insmed had a negative return on equity of 87.35% and a negative net margin of 162.82%. Insmed's revenue was up 68.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.96) EPS. View Insmed's earnings history.

8 equities research analysts have issued 1 year price targets for Insmed's shares. Their forecasts range from $20.00 to $56.00. On average, they expect Insmed's share price to reach $42.00 in the next twelve months. This suggests a possible upside of 68.3% from the stock's current price. View analysts' price targets for Insmed.

Press coverage about INSM stock has trended somewhat positive on Friday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Insmed earned a news sentiment score of 0.7 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutInsmed.

Insmed saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 13,480,000 shares, an increase of 12.2% from the April 15th total of 12,010,000 shares. Based on an average trading volume of 1,440,000 shares, the days-to-cover ratio is currently 9.4 days. Currently, 15.8% of the shares of the company are short sold. View Insmed's Current Options Chain.

Some companies that are related to Insmed include Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Mylan (MYL), Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Myokardia (MYOK) and Forty Seven (FTSV). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include AbbVie (ABBV), Geron (GERN), Johnson & Johnson (JNJ), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Intercept Pharmaceuticals (ICPT), Micron Technology (MU), Opko Health (OPK) and Amarin (AMRN).

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Insmed's stock is owned by many different retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (9.83%), Franklin Resources Inc. (2.21%), Eagle Asset Management Inc. (1.67%), Geode Capital Management LLC (1.48%), Carillon Tower Advisers Inc. (1.25%) and Fairmount Funds Management LLC (1.14%). Company insiders that own Insmed stock include Alfred Altomari, Donald J Hayden Jr, John Goll, Melvin Md Sharoky, Orlov S Nicole Schaeffer, Roger Adsett, Steinar J Engelsen and William Lewis. View institutional ownership trends for Insmed.

INSM stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Russell Investments Group Ltd., Foresite Capital Management IV LLC, Foresite Capital Management II LLC, JPMorgan Chase & Co., Granahan Investment Management Inc. MA, Raymond James & Associates, and Rafferty Asset Management LLC. Company insiders that have sold Insmed company stock in the last year include John Goll, Orlov S Nicole Schaeffer, and William Lewis. View insider buying and selling activity for Insmed.

INSM stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., William Blair Investment Management LLC, AXA, Cormorant Asset Management LP, Lord Abbett & CO. LLC, Scout Investments Inc., Geode Capital Management LLC, and WCM Investment Management LLC. Company insiders that have bought Insmed stock in the last two years include Melvin Md Sharoky, Roger Adsett, Steinar J Engelsen, and William Lewis. View insider buying and selling activity for Insmed.

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INSM stock can currently be purchased for approximately $24.95.

Insmed has a market capitalization of $2.52 billion and generates $136.47 million in revenue each year. The biopharmaceutical company earns $-254,340,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. Insmed employs 373 workers across the globe.

The official website for Insmed is www.insmed.com.

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]